Orlando Health

410 Medical is a healthcare company based in Durham, North Carolina, founded in 2013. It specializes in developing a rapid infuser device designed to assist critically ill patients who require volume resuscitation. This innovative solution enables healthcare providers to quickly deliver fluids, including blood and other essential components, thereby enhancing the speed and efficiency of care for patients facing life-threatening conditions like sepsis and shock. The device allows for fast setup and minimizes provider fatigue, enabling a single healthcare provider to manage multiple patient care issues simultaneously. It is particularly beneficial in pre-hospital settings and emergency departments, where timely intervention is crucial and resources may be constrained.

EvidenceCare, LLC is a company that designs and develops decision support tools and web applications for clinicians, aimed at enhancing the delivery of medical care and treatment procedures. Established in 2014 and based in Brentwood, Tennessee, EvidenceCare offers a clinical decision support system (CDSS) that integrates seamlessly into a clinician's electronic health record (EHR) workflow. This platform provides customized, interactive guidance to healthcare providers, promoting evidence-based care with measurable outcomes. Key features of EvidenceCare include Pathway Builder, which allows health systems to create tailored care pathways; Admission Criteria, designed to minimize denial rates and maximize reimbursements for hospitals; and Imaging Criteria, which ensures compliance with appropriate use criteria for advanced imaging services. By leveraging advanced CDSS technology, EvidenceCare helps healthcare organizations improve quality and safety, reduce liability, enhance operational efficiency, and capture additional revenue while adhering to government compliance requirements.

Francis Medical, Inc., established in 2018 and based in Maple Grove, Minnesota, specializes in the development of innovative medical devices utilizing water vapor technology to treat various urological cancers. The company focuses on prostate, kidney, and bladder cancers, aiming to provide minimally invasive, transurethral procedures that can potentially reduce life-altering side effects common in traditional treatments.

G.I. Windows, Inc. is a clinical-stage company based in West Bridgewater, Massachusetts, specializing in the manufacture of medical devices that utilize surgical anastomotic technology. Founded in 2012, the company aims to revolutionize surgical procedures by developing less invasive techniques for treating obesity and type 2 diabetes. G.I. Windows is focused on creating innovative solutions that not only enhance patient outcomes but also contribute to cost reduction in the healthcare system. Through its commitment to advancing surgical technology, the company seeks to establish a new category in healthcare, enabling the development of procedures that are novel and less invasive.

Brookwood Baptist Health operates a comprehensive healthcare network in Birmingham, Alabama, comprising five acute care hospitals, a primary care network, and diagnostic and surgical centers. The company offers a wide range of services, including emergency care, telehealth appointments, and Medicaid resources, tailoring treatments to individual patient needs. It aims to build trust and foster meaningful relationships within the communities it serves.

Endogenex is a medical technology company founded in 2017 that focuses on developing an innovative endoscopic procedure to assist patients with type 2 diabetes in managing their blood glucose levels. The company has created a unique therapy that employs pulsed electric fields to promote the regeneration of the duodenal mucosa, which contributes to enhanced glycemic control. By providing this novel treatment option, Endogenex aims to improve the quality of life for individuals living with type 2 diabetes.

Arrivo BioVentures LLC is a biopharmaceutical company based in Morrisville, North Carolina, established in 2015. The company specializes in the development of biologics and small molecules aimed at enhancing patient care. Arrivo BioVentures focuses on reformulating existing drugs and creating new chemical entities, employing its expertise to navigate regulatory strategies that streamline the approval process. By collaborating closely with regulatory bodies such as the FDA, the company aims to minimize unexpected challenges and accelerate the implementation of its clinical programs. Through its innovative approach, Arrivo BioVentures seeks to meet the demands of the biotechnology sector while prioritizing the improvement of patient outcomes.

410 Medical is a healthcare company based in Durham, North Carolina, founded in 2013. It specializes in developing a rapid infuser device designed to assist critically ill patients who require volume resuscitation. This innovative solution enables healthcare providers to quickly deliver fluids, including blood and other essential components, thereby enhancing the speed and efficiency of care for patients facing life-threatening conditions like sepsis and shock. The device allows for fast setup and minimizes provider fatigue, enabling a single healthcare provider to manage multiple patient care issues simultaneously. It is particularly beneficial in pre-hospital settings and emergency departments, where timely intervention is crucial and resources may be constrained.

Sensydia Corp is a company focused on developing innovative cardiovascular care equipment, particularly through its Sensydia Cardiac Performance System (CPS). This portable, point-of-care hemodynamic measurement platform utilizes proprietary sensor technology and machine learning to non-invasively assess critical cardiac metrics such as ejection fraction, cardiac output, and pulmonary artery pressure. The CPS is designed for use in various settings, including hospitals, medical offices, and telemedicine environments, allowing for rapid screening and detection of cardiac abnormalities. By providing accessible hemodynamic insights comparable to routine blood pressure readings, Sensydia aims to facilitate early disease detection and enhance management for conditions like heart failure and pulmonary hypertension. Founded in 2015 and headquartered in Los Angeles, California, the company seeks to improve patient outcomes while reducing healthcare costs through accurate and efficient monitoring solutions.

410 Medical is a healthcare company based in Durham, North Carolina, founded in 2013. It specializes in developing a rapid infuser device designed to assist critically ill patients who require volume resuscitation. This innovative solution enables healthcare providers to quickly deliver fluids, including blood and other essential components, thereby enhancing the speed and efficiency of care for patients facing life-threatening conditions like sepsis and shock. The device allows for fast setup and minimizes provider fatigue, enabling a single healthcare provider to manage multiple patient care issues simultaneously. It is particularly beneficial in pre-hospital settings and emergency departments, where timely intervention is crucial and resources may be constrained.

Vergent Bioscience, Inc. specializes in developing tumor-targeted fluorescent probes that enhance the surgical removal of cancerous tissue. Founded in 2013 and based in Minneapolis, Minnesota, the company’s flagship product, VGT-309, is a molecularly-targeted imaging molecule designed to bind to enzymes overexpressed in various tumor tissues. Upon injection before surgery, VGT-309 activates a brightly fluorescing dye, enabling surgeons to visually distinguish cancerous tissue from normal tissue during procedures. This technology aims to improve surgical outcomes by ensuring the complete removal of tumors, which is crucial for increasing cure rates. Vergent Bioscience's innovative approach addresses a significant clinical need for advanced visualization in various surgical settings, including open, laparoscopic, and robotic surgeries.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Florida Heart & Vascular Center offers services that are far-reaching in breadth and scope and a team of consultative.

BioStable Science & Engineering, Inc. is a cardiovascular device company based in Austin, Texas, that specializes in developing valve repair technologies as alternatives to valve replacement for patients with aortic valve disease. The company offers a range of HAART aortic valve repair technologies, including the HAART 300 aortic annuloplasty device, designed to reduce annular dilatation and restore three-dimensional annular geometry, and the HAART 200 device tailored for bicuspid aortic valve repair. Additionally, BioStable's aortic root restoration system aims to enhance surgical outcomes for patients with aortic insufficiency or aortic root aneurysm. Founded in 2008, BioStable leverages its expertise in product development, regulatory affairs, and clinical validation to minimize time to market for its innovative medical devices, ultimately improving patient care in the cardiovascular field.

Phynd Technologies Inc. operates a Software-as-a-Service data management platform designed to streamline healthcare provider data management for healthcare organizations in the United States. The company's Unified Provider Management (UPM) platform centralizes critical provider data, enabling organizations to effectively gather, manage, and share information across various IT systems. This enhances financial performance and clinical outcomes while minimizing compliance risks. Key features of the platform include tools for managing billing addresses, communication preferences, licensing, and provider enrollment in real-time. Phynd's services are utilized by over 350 hospitals and more than 20,000 locations across the country, allowing these entities to maintain a comprehensive hub of provider data for applications in electronic health records, marketing, and claims systems. Founded in 2012 and headquartered in Dallas, Texas, Phynd Technologies has established partnerships to further enhance its service offerings.

Gauss Surgical, Inc. specializes in real-time blood monitoring solutions that enhance clinical decision-making in the healthcare sector. The company has developed a vision-based platform that provides accurate estimations of blood loss, facilitating timely transfusion decisions and improving patient outcomes. Its flagship product, Triton, is utilized in obstetrics to aid in the early detection of postpartum hemorrhage and offers objective metrics for assessing blood loss. Additionally, Gauss Surgical offers Triton OR, designed for operating rooms to measure blood loss from surgical sponges and suction canisters, and Triton L&D, which focuses on vaginal delivery and postpartum care. Founded in 2011, Gauss Surgical operates from its headquarters in Menlo Park, California.

MRI